Aardvark Therapeutics (AARD) Income towards Parent Company (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Income towards Parent Company data on file, last reported at -$21.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 132.09% year-over-year to -$21.6 million; the trailing twelve-month figure through Mar 2026 stood at -$69.9 million (down 127.08% YoY), and the FY2025 full-year result was -$69.9 million, down 80.24% from the prior year.
• Income towards Parent Company fell to -$21.6 million in Q1 2026, from -$17.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$2.1 million in Q1 2024 to a low of -$21.6 million in Q1 2026.
• A 3-year average of -$11.4 million and a median of -$11.9 million in 2024 frame the typical range for Income towards Parent Company.
• Peak annual rise in Income towards Parent Company reached 47.62% in 2025, while the deepest fall reached 349.52% in 2025.
• Tracing AARD's Income towards Parent Company over 3 years: stood at -$11.9 million in 2024, then tumbled by 47.62% to -$17.6 million in 2025, then decreased by 22.73% to -$21.6 million in 2026.
• Business Quant data shows AARD's Income towards Parent Company at -$21.6 million in Q1 2026, -$17.6 million in Q4 2025, and -$16.4 million in Q3 2025.